Bank of America Initiated Sangamo Therapeutics (SGMO)’s Coverage with $24 Target; 8 Bullish Analysts Covering Kirby (KEX)

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Logo

Among 15 analysts covering Kirby (NYSE:KEX), 8 have Buy rating, 1 Sell and 6 Hold. Therefore 53% are positive. Kirby had 41 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Kirby Corporation (NYSE:KEX) earned “Buy” rating by Jefferies on Monday, December 18. The stock has “Buy” rating by Jefferies on Tuesday, May 30. On Tuesday, January 16 the stock rating was initiated by Gabelli with “Hold”. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, July 31. Bank of America maintained the shares of KEX in report on Thursday, February 1 with “Underperform” rating. The firm has “Buy” rating by BB&T Capital given on Monday, May 2. The firm has “Sector Perform” rating by RBC Capital Markets given on Thursday, January 28. The company was maintained on Thursday, April 5 by Stifel Nicolaus. Jefferies maintained Kirby Corporation (NYSE:KEX) on Wednesday, March 9 with “Buy” rating. The firm has “Buy” rating by Stifel Nicolaus given on Friday, May 25. See Kirby Corporation (NYSE:KEX) latest ratings:

25/05/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $96 New Target: $103 Maintain
01/05/2018 Broker: Wells Fargo Old Rating: Outperform New Rating: Outperform Old Target: $89 New Target: $100 Maintain
27/04/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $88 New Target: $94 Maintain
05/04/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $88 Maintain
02/02/2018 Broker: Evercore Old Rating: Hold New Rating: Outperform New Target: $86 Upgrade
02/02/2018 Broker: Stephens Rating: Hold New Target: $78.0 Maintain
01/02/2018 Broker: Jefferies Rating: Buy New Target: $90.0 Maintain
01/02/2018 Broker: Bank of America Old Rating: Underperform New Rating: Underperform Old Target: $65 New Target: $66 Maintain
22/01/2018 Broker: Wells Fargo Rating: Buy New Target: $83.0 Upgrade
16/01/2018 Broker: Gabelli Rating: Hold New Target: $80.0 Initiate

In a an analyst note released on 20 June, Bank of America analyst just has initiated coverage of Sangamo Therapeutics (NASDAQ:SGMO) with Buy rating. The target price is exactly $24.

Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 7 have Buy rating, 1 Sell and 2 Hold. Therefore 70% are positive. Sangamo Biosciences has $33.0 highest and $4 lowest target. $23.20’s average target is 41.03% above currents $16.45 stock price. Sangamo Biosciences had 27 analyst reports since August 8, 2015 according to SRatingsIntel. On Thursday, June 22 the stock rating was reinitiated by Jefferies with “Buy”. The firm earned “Buy” rating on Tuesday, September 12 by Jefferies. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) earned “Buy” rating by JP Morgan on Thursday, September 3. The rating was maintained by Wedbush with “Hold” on Tuesday, March 13. The stock has “Hold” rating by Wedbush on Monday, May 21. Wells Fargo maintained the stock with “Buy” rating in Thursday, February 22 report. The firm earned “Buy” rating on Friday, October 23 by Jefferies. The rating was downgraded by Janney Capital to “Neutral” on Thursday, August 4. The company was maintained on Thursday, February 22 by Piper Jaffray. The rating was upgraded by PiperJaffray on Wednesday, November 15 to “Overweight”.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.67 billion. The company??s proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

Since January 2, 2018, it had 0 buys, and 19 selling transactions for $2.88 million activity. Mento Steven J sold $132,758 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on Monday, April 2. Shares for $92,436 were sold by Conner Edward R.. On Monday, April 2 Herberts Curt A. III sold $41,684 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) or 2,278 shares. Another trade for 5,000 shares valued at $127,812 was sold by Yi Kathy. Shares for $235,080 were sold by Ramasastry Saira.

More notable recent Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news were published by: which released: “Sangamo Therapeutics: Investability Outlook” on June 13, 2018, also with their article: “UPDATE: BofA/Merrill Lynch Starts Sangamo BioSciences (SGMO) at Buy Citing Upcoming Catalysts” published on June 20, 2018, published: “Crispr On Hold While Sangamo Accelerates” on June 04, 2018. More interesting news about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) were released by: and their article: “New Research Coverage Highlights Accenture, Chico’s FAS, The Allstate, Sangamo Therapeutics, ABB, and First …” published on June 13, 2018 as well as‘s news article titled: “Growing Demand for Biotechnologies are Expected to Grow” with publication date: June 18, 2018.

The stock increased 3.13% or $0.5 during the last trading session, reaching $16.45. About 1.82M shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 100.00% since June 20, 2017 and is uptrending. It has outperformed by 87.43% the S&P500. Some Historical SGMO News: 03/05/2018 – Sangamo Therapeutics Announces Senior Leadership Changes; 03/05/2018 – Sangamo Therapeutics: Michael Holmes Promoted to Chief Technology Officer; 21/03/2018 – Glancy Prongay & Murray LLP Announces Investigation on Behalf of Sangamo Therapeutics, Inc. Investors (SGMO); 24/04/2018 – Sangamo Therapeutics Announces Proposed Public Offering of Common Stk; 24/04/2018 – SANGAMO THERAPEUTICS – SEES USING NET PROCEEDS FROM OFFERING TO SUPPORT OWN, PARTNERED GENE THERAPY, GENOME EDITING, CELL THERAPY, AMONG OTHER THINGS; 03/05/2018 – SANGAMO THERAPEUTICS REPORTS SR LEADERSHIP CHANGES; 23/05/2018 – Biotech Analysis Central Preview Series: Sangamo Therapeutics; 24/04/2018 – Sangamo Therapeutics Plans $200 Million Share Offering; 17/04/2018 – SANGAMO THERAPEUTICS-INVESTIGATION DID NOT REVEAL EVIDENCE THAT ACCESS TO PERSONAL INFO ABOUT PATIENTS OR OTHER INDIVIDUALS WAS AFFECTED BY INCIDENT; 16/05/2018 – BIOVERATIV & SANGAMO REPORT FDA ACCEPTANCE OF IND APPLICATION

Investors sentiment decreased to 1.24 in 2018 Q1. Its down 0.16, from 1.4 in 2017Q4. It dived, as 12 investors sold Sangamo Therapeutics, Inc. shares while 62 reduced holdings. 46 funds opened positions while 46 raised stakes. 53.36 million shares or 0.26% more from 53.22 million shares in 2017Q4 were reported. Davenport Company Limited Liability Company stated it has 65,500 shares or 0% of all its holdings. Foresite Cap Mgmt Ii Ltd Limited Liability Company owns 0.29% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 46,138 shares. Voya Mngmt Ltd Liability Co, a Georgia-based fund reported 37,034 shares. Pnc Serv Group has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). The California-based Eam Ltd Liability has invested 0.69% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Citigroup holds 123,858 shares. Meeder Asset Mgmt reported 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). National Bank Of Montreal Can reported 53,638 shares stake. Alliancebernstein Lp reported 179,803 shares. Bailard Inc holds 0.02% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) or 20,000 shares. Point72 Asia (Hong Kong) Limited stated it has 0.01% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Fmr, a Massachusetts-based fund reported 4.25M shares. Ameriprise Inc accumulated 127,375 shares or 0% of the stock. First Mercantile Com holds 0.03% or 7,666 shares. Great West Life Assurance Can reported 12,767 shares.

Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on August, 8. They expect $-0.13 earnings per share, up 23.53% or $0.04 from last year’s $-0.17 per share. After $-0.23 actual earnings per share reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -43.48% EPS growth.

The stock decreased 0.29% or $0.25 during the last trading session, reaching $84.5. About 734,481 shares traded or 47.70% up from the average. Kirby Corporation (NYSE:KEX) has risen 33.85% since June 20, 2017 and is uptrending. It has outperformed by 21.28% the S&P500. Some Historical KEX News: ; 25/04/2018 – Kirby Corp 1Q EPS 54c; 03/05/2018 – KIRBY CORP – BARGES WILL BE ABOUT $0.02 PER SHARE ACCRETIVE IN 2018; 03/05/2018 – KIRBY CORP KEX.N -PURCHASE WILL BE FINANCED THROUGH ADDITIONAL BORROWINGS; 03/05/2018 – Kirby Corporation Signs Agreement To Purchase Pressure Barges From Targa Resources Corp; 25/04/2018 – KIRBY CORP – EXPECTS 2018 CAPITAL SPENDING TO BE IN $200 TO $225 MLN RANGE; 03/05/2018 – KIRBY CORP KEX.N -AGREEMENT TO ACQUIRE TARGA RESOURCES CORP’S INLAND MARINE TANK BARGE BUSINESS FOR APPROXIMATELY $69.3 MLN IN CASH; 03/05/2018 – Kirby Corp Sees Deal Closing End 2; 03/05/2018 – Kirby Corp Agrees to Purchase Pressure Barges From Targa Resources Corp; 25/04/2018 – Kirby Corp Cuts FY18 View To EPS $2.15-EPS $2.65; 03/05/2018 – KIRBY IN PACT TO BUY PRESSURE BARGES FOR $69.3M IN CASH

Investors sentiment decreased to 0.87 in 2018 Q1. Its down 0.18, from 1.05 in 2017Q4. It worsened, as 16 investors sold Kirby Corporation shares while 87 reduced holdings. 36 funds opened positions while 54 raised stakes. 54.19 million shares or 1.23% less from 54.86 million shares in 2017Q4 were reported. Cornerstone Advisors Inc invested in 0% or 90 shares. Arrowmark Colorado Holdg Ltd, Colorado-based fund reported 2.71 million shares. First Trust Advsrs Limited Partnership owns 328,668 shares or 0.06% of their US portfolio. Stratos Wealth Partners Ltd holds 6 shares. Ameriprise reported 148,011 shares or 0.01% of all its holdings. Federated Pa invested 0.01% in Kirby Corporation (NYSE:KEX). Guggenheim Cap reported 52,547 shares. Rhumbline Advisers has 0.01% invested in Kirby Corporation (NYSE:KEX) for 93,207 shares. Crestwood Mngmt Limited Partnership invested in 4.2% or 91,638 shares. Schwab Charles Incorporated has invested 0.02% in Kirby Corporation (NYSE:KEX). Advsrs Asset Mngmt holds 0.01% in Kirby Corporation (NYSE:KEX) or 5,250 shares. Stone Run Capital Lc has 0.6% invested in Kirby Corporation (NYSE:KEX). Paloma invested in 0.01% or 11,400 shares. Baldwin Brothers Inc Ma accumulated 0% or 350 shares. Citigroup Inc holds 0% or 8,597 shares in its portfolio.

Another recent and important Kirby Corporation (NYSE:KEX) news was published by which published an article titled: “New Research: Key Drivers of Growth for CBIZ, Range Resources, Pepsico, Kirby, Moog, and American Water Works …” on June 11, 2018.

Kirby Corporation (NYSE:KEX) Institutional Positions Chart